However, over-expression of RSK3 or RSK4 promotes proliferation of ER/PR-positive MCF7 breast cancer cells upon inhibition of PI3K/mTORC1 pathway and promotes resistance to PI3K inhibitor in a xenograft model [5]. Here, RPS6KA2 is linked to breast carcinoma.